Cognia Corporation Forms Foundation of Scientific Advisory Board

Christian Burks, Daniel Finley, and Edgar Wingender Join Vincent Marchesi

And Cognia Team



Apr 23, 2001, 01:00 ET from Cognia Corporation

    NEW YORK, April 23 /PRNewswire Interactive News Release/ --
 Cognia Corporation announced today that Christian Burks, Daniel Finley, and
 Edgar Wingender will join Vincent Marchesi, a Cognia co-founder, in forming
 its Scientific Advisory Board.
     "The depth of bioinformatic, proteomic, medical, and biotech industry
 experience represented by these four individuals considerably strengthens
 Cognia as it builds a leadership position in the field of molecular biology
 databases and software tools," said David M. Rubin, Ph.D., Cognia's President
 and Chief Executive Officer.  "Dr. Marchesi and team will help guide the next
 phase of our business from value-added distributor to developer of innovative
 proprietary products."
     Dr. Marchesi heads the Boyer Center for Molecular Medicine at the Yale
 School of Medicine where he is also Professor of Pathology and Cell Biology.
 Dr. Marchesi is a member of the National Academy of Sciences and the Institute
 of Medicine, and is currently the Editor-in-Chief of the FASEB Journal.
 Dr. Marchesi has published over 150 scientific papers and reviews on a broad
 range of topics.  In addition to co-founding Cognia, he co-founded
 Molecular Diagnostics, Inc., and served on the Board of Directors of the
 American Cyanamid Company.
     Dr. Burks is a Vice President and the Chief Informatics Officer of
 Exelixis.  Previously, while at Los Alamos National Laboratory, he helped
 create GenBank, the global DNA sequence database resource.  Dr. Burks also
 served as Principal Investigator for GenBank, Group Leader of the
 Theoretical Biology & Biophysics Group, and Laboratory-wide Program Leader for
 Computational Biology.  He has co-authored numerous publications in
 bioinformatics and served on a number of national and international editorial,
 review and advisory boards.  Dr. Burks received his Ph.D. in Molecular
 Biophysics and Biochemistry from Yale University.
     Dr. Finley has been a professor of Molecular and Cellular Physiology and
 Cell Biology at Harvard Medical School since 1988.  He has published over
 30 original papers and 23 reviews, and has edited a leading book in the field
 of protein regulation with an emphasis on ubiquitin-dependent turnover and the
 proteasome.  He has served on several study sections including the NIH study
 sections for Biochemistry and Microbial Physiology and the ACS study section
 for Genetics and Microbiology.  Dr. Finley is on the editorial board of
 Molecular and Cellular Biology and is the FASEB Ubiquitin Conference co-Chair
 2001 and Conference Chair 2003.  Dr. Finley received a Ph.D. in biology from
 MIT and did his undergraduate work in molecular biology at Harvard University.
     Dr. Wingender is co-founder, President and Chief Scientific Officer of
 BIOBASE GmbH, a leading molecular biology database and software company.
 Dr. Wingender has been head of Bioinformatics at the GBF (German Research
 Centre for Biotechnology) in Braunschweig since 1993.  Dr. Wingender worked on
 gene regulation and protein design at the University of Marburg and GBF,
 before moving into the field of bioinformatics.  Dr. Wingender has more than
 70 scientific publications, including a text book on gene regulation.  Since
 1996, he has been chairman of the association Bioinformation Systems e.V.,
 where he operates as Editor-in-Chief of the scientific online journal
 "In Silico Biology."
 
     About Cognia
     Cognia is a developer and distributor of knowledge-based products that
 facilitate the use of genomic, proteomic and cellomic/physiological
 information.  Cognia provides integrated suites of high-quality, annotated
 databases, cutting edge bioinformatics tools, and associated consulting and
 training services to accelerate drug discovery and basic research.  Cognia's
 products and services help pharmaceutical and biotechnology companies to
 efficiently and cost-effectively discover and develop new drugs, by
 accelerating research processes.  Cognia's customers include leading
 pharmaceutical and biotechnology companies such as Schering-Plough, Eli Lilly,
 Berlex Biosciences, Scios as well as Harvard Medical School and University of
 Cincinnati.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X79555057
 
 

SOURCE Cognia Corporation
    NEW YORK, April 23 /PRNewswire Interactive News Release/ --
 Cognia Corporation announced today that Christian Burks, Daniel Finley, and
 Edgar Wingender will join Vincent Marchesi, a Cognia co-founder, in forming
 its Scientific Advisory Board.
     "The depth of bioinformatic, proteomic, medical, and biotech industry
 experience represented by these four individuals considerably strengthens
 Cognia as it builds a leadership position in the field of molecular biology
 databases and software tools," said David M. Rubin, Ph.D., Cognia's President
 and Chief Executive Officer.  "Dr. Marchesi and team will help guide the next
 phase of our business from value-added distributor to developer of innovative
 proprietary products."
     Dr. Marchesi heads the Boyer Center for Molecular Medicine at the Yale
 School of Medicine where he is also Professor of Pathology and Cell Biology.
 Dr. Marchesi is a member of the National Academy of Sciences and the Institute
 of Medicine, and is currently the Editor-in-Chief of the FASEB Journal.
 Dr. Marchesi has published over 150 scientific papers and reviews on a broad
 range of topics.  In addition to co-founding Cognia, he co-founded
 Molecular Diagnostics, Inc., and served on the Board of Directors of the
 American Cyanamid Company.
     Dr. Burks is a Vice President and the Chief Informatics Officer of
 Exelixis.  Previously, while at Los Alamos National Laboratory, he helped
 create GenBank, the global DNA sequence database resource.  Dr. Burks also
 served as Principal Investigator for GenBank, Group Leader of the
 Theoretical Biology & Biophysics Group, and Laboratory-wide Program Leader for
 Computational Biology.  He has co-authored numerous publications in
 bioinformatics and served on a number of national and international editorial,
 review and advisory boards.  Dr. Burks received his Ph.D. in Molecular
 Biophysics and Biochemistry from Yale University.
     Dr. Finley has been a professor of Molecular and Cellular Physiology and
 Cell Biology at Harvard Medical School since 1988.  He has published over
 30 original papers and 23 reviews, and has edited a leading book in the field
 of protein regulation with an emphasis on ubiquitin-dependent turnover and the
 proteasome.  He has served on several study sections including the NIH study
 sections for Biochemistry and Microbial Physiology and the ACS study section
 for Genetics and Microbiology.  Dr. Finley is on the editorial board of
 Molecular and Cellular Biology and is the FASEB Ubiquitin Conference co-Chair
 2001 and Conference Chair 2003.  Dr. Finley received a Ph.D. in biology from
 MIT and did his undergraduate work in molecular biology at Harvard University.
     Dr. Wingender is co-founder, President and Chief Scientific Officer of
 BIOBASE GmbH, a leading molecular biology database and software company.
 Dr. Wingender has been head of Bioinformatics at the GBF (German Research
 Centre for Biotechnology) in Braunschweig since 1993.  Dr. Wingender worked on
 gene regulation and protein design at the University of Marburg and GBF,
 before moving into the field of bioinformatics.  Dr. Wingender has more than
 70 scientific publications, including a text book on gene regulation.  Since
 1996, he has been chairman of the association Bioinformation Systems e.V.,
 where he operates as Editor-in-Chief of the scientific online journal
 "In Silico Biology."
 
     About Cognia
     Cognia is a developer and distributor of knowledge-based products that
 facilitate the use of genomic, proteomic and cellomic/physiological
 information.  Cognia provides integrated suites of high-quality, annotated
 databases, cutting edge bioinformatics tools, and associated consulting and
 training services to accelerate drug discovery and basic research.  Cognia's
 products and services help pharmaceutical and biotechnology companies to
 efficiently and cost-effectively discover and develop new drugs, by
 accelerating research processes.  Cognia's customers include leading
 pharmaceutical and biotechnology companies such as Schering-Plough, Eli Lilly,
 Berlex Biosciences, Scios as well as Harvard Medical School and University of
 Cincinnati.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X79555057
 
 SOURCE  Cognia Corporation